Amyloidosis management strategies in adults
Amyloidosis is a complex and rare group of diseases characterized by the abnormal deposition of amyloid proteins in various tissues and organs. This accumulation can impair normal organ function, leading to a spectrum of clinical manifestations that vary depending on the organs affected. Managing amyloidosis in adults requires a comprehensive, individualized approach that aims to reduce amyloid production, manage symptoms, and prevent organ damage.
The cornerstone of treatment involves targeting the underlying cause of amyloid deposition. For example, in light-chain (AL) amyloidosis, which is associated with plasma cell dyscrasias such as multiple myeloma, therapies aim to suppress abnormal plasma cell clones. Chemotherapy regimens similar to those used in multiple myeloma—comprising agents like bortezomib, cyclophosphamide, and dexamethasone—are often employed to reduce the production of amyloidogenic light chains. More recently, monoclonal antibodies targeting plasma cells, such as daratumumab, have shown promising results in depleting amyloid-producing cells.
In cases of transthyretin (ATTR) amyloidosis, where misfolded transthyretin proteins deposit in tissues, treatment strategies differ. For hereditary ATTR amyloidosis, options include liver transplantation, since the liver produces most of the mutant transthyretin, and the use of transthyretin stabilizers like tafamidis that prevent tetramer dissociation and subsequent amyloid formation. In wild-type ATTR amyloidosis, often seen in the elderly, stabilizers and novel agents like patisiran and inotersen, which are gene silencers, are utilized to reduce transthyretin production.
Supportive care forms an integral component of amyloidosis management. This involves symptomatic treatment tailored to the specific organ systems affected. For cardiac amyloidosis, diuretics are used to alleviate congestive symptoms, while arrhythmias may require device implantation or pharmacotherapy. Renal involvement may necessitate dialysis in advanced cases. For gastrointestinal or neurological involvement, nutritional support and symptom-specific therapies are essential.
Monitoring disease progression and treatment response is critical and involves regular assessment through laboratory tests, imaging studies, and biopsies when appropriate. Cardiac MRI, echocardiography, and biomarker levels such as NT-proBNP and troponins help evaluate cardiac function, while serum free light chains and immunofixation are used in AL amyloidosis to monitor plasma cell activity.
Emerging therapies and ongoing research continue to refine management strategies. Novel agents targeting amyloid deposits directly, immunotherapies aiming to enhance amyloid clearance, and gene editing technologies hold promise for future treatment of amyloidosis. Multidisciplinary care teams—including hematologists, cardiologists, neurologists, and nephrologists—are essential to optimize outcomes and improve quality of life for affected adults.
In conclusion, managing amyloidosis in adults requires a nuanced approach that addresses the underlying cause, manages symptoms, and monitors disease progression. Advances in targeted therapies and supportive care have significantly improved prognosis, but ongoing research remains vital to develop more effective treatments.
